BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...
Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...
Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...
The FDA has approved Apidra SoloSTAR (insulin glulisine[rDNA origin] injection, from sanofi-aventis), a prefilled disposable pencontaining Apidra. Apidra SoloSTAR makes administration of insulin ...
Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...
Apidra SoloSTAR (insulin glulisine [rDNA origin] injection, from sanofi-aventis), a prefilled disposable pen containing Apidra, is now available. Apidra SoloSTAR makes administration of insulin more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback